Sign Up to like & get
recommendations!
1
Published in 2022 at "Phytotherapy Research"
DOI: 10.1002/ptr.7384
Abstract: Crocin has been extensively investigated in treating neurodegenerative diseases. However, its effect on cognitive impairment associated with atherosclerosis remains unknown. The present study aimed to explore the potential mechanism of crocin on cognitive impairment in…
read more here.
Keywords:
cognitive impairment;
associated atherosclerosis;
crocin;
impairment associated ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Synapse"
DOI: 10.1002/syn.22134
Abstract: Synapse impairment is associated with post‐traumatic stress disorder (PTSD), which is characterized by enhanced apoptosis in the hippocampus, amygdala, and other brain regions. However, there are no detailed studies on the relationship between apoptosis and…
read more here.
Keywords:
enhanced apoptosis;
synapse impairment;
apoptosis;
impairment associated ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Psychological Medicine"
DOI: 10.1017/s0033291717003774
Abstract: Abstract Background Cognitive deficits are a core feature of early stages in schizophrenia. However, the extent to which antipsychotic (AP) have a deleterious effect on cognitive performance remains under debate. We aim to investigate whether…
read more here.
Keywords:
first episode;
cognitive impairment;
impairment;
episode psychosis ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "PLoS Genetics"
DOI: 10.1371/journal.pgen.1008826
Abstract: Hearing loss (HL) is one of the most common sensory impairments and etiologically and genetically heterogeneous disorders in humans. Muscular dystrophies (MDs) are neuromuscular disorders characterized by progressive degeneration of skeletal muscle accompanied by non-muscular…
read more here.
Keywords:
cochlear;
hearing impairment;
glycosylation;
cochlear nerve ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Frontiers in Psychiatry"
DOI: 10.3389/fpsyt.2019.00648
Abstract: There are currently no regulatory approved pharmacological treatments for cognitive impairment associated with schizophrenia (CIAS). One possibility is that trial methodology itself is hindering their development. Emerging evidence suggests that patients with schizophrenia may show…
read more here.
Keywords:
schizophrenia;
pharmacotherapy trials;
cognitive impairment;
impairment ... See more keywords